Streetbeat News

Stock Prices

CARS

In the past three months, five analysts have provided ratings for Cars.com (NYSE:CARS), ranging from bullish to bearish. The average 12-month price target is $22.8, with a high of $26.00 and a low of $19.00. Recent analyst actions include downgrades and maintained ratings, reflecting changing market dynamics and company performance. Cars.com has shown positive revenue growth and strong net margins but faces challenges with return on equity.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 9:00 pm

TPVG

TriplePoint Venture Growth (NYSE: TPVG) has received mixed analyst ratings over the past three months, with a majority leaning towards 'Somewhat Bearish'. The average 12-month price target has decreased from $9.25 to $8.38. Analysts from firms like Keefe, Bruyette & Woods, Piper Sandler, and Wells Fargo have lowered their ratings and price targets. Despite strong financial metrics like a high net margin and ROE, TPVG faces challenges with its ROA and revenue growth compared to industry peers.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 9:00 pm

FTAI

FTAI Aviation (NASDAQ:FTAI) has significantly outperformed the market over the past 5 years, with an average annual return of 52.33%. A $100 investment in FTAI 5 years ago would now be worth $818.50. The article highlights the impact of compounded returns on investment growth.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 9:00 pm

AMN

Three analysts have recently evaluated AMN Healthcare Services (NYSE:AMN), with mixed ratings. The average 12-month price target is $67.0, down 2.9% from the previous $69.00. Key analysts have adjusted their ratings and price targets, reflecting varied sentiments about the company's performance.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 9:00 pm

MPC

Marathon Petroleum (NYSE:MPC) has significantly outperformed the market over the past 5 years, delivering an average annual return of 30.11%. A $100 investment in MPC 5 years ago would now be worth $379.35. The article highlights the impact of compounded returns on investment growth.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 9:00 pm

JANX

Analysts have provided mixed evaluations for Janux Therapeutics (NASDAQ:JANX) over the past three months, with ratings ranging from bullish to bearish. The average 12-month price target is $65.2, with a high of $100.00 and a low of $42.00. Recent analyst actions include a lowered target by Scotiabank and maintained targets by Cantor Fitzgerald and Wedbush.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 9:00 pm

ZVSA

ZyVersa Therapeutics (NASDAQ:ZVSA) reported a Q2 EPS of $(3.31), beating the analyst consensus estimate of $(3.75) by 11.73%. This represents a significant improvement over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 8:40 pm

DWAC

Trump Media & Technology Group has stated in an SEC filing that it does not have substantial doubt about its ability to continue as a going concern as of June 30.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 8:39 pm

PRZO

ParaZero Technologies has filed for a mixed shelf offering of up to $50 million, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 8:38 pm

SBUX

Starbucks shares are trading higher following a report suggesting that activist investor Starboard Value has a stake in the company.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 8:36 pm